Chest
-
Infectious Disease Case Reports Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Neutropenia complicates the management of critically ill patients. In the absence of malignancy or chemotherapy, its etiology and manifestations can be difficult to identify and portend a poor prognosis. Presented is a case of Neutropenic Enterocolitis (NEC). ⋯ Although a rare complication of medications, neutropenia resulting in NEC is unfortunate and potentially deadly. The case demonstrates the importance of follow up laboratory evaluation by primary care physicians after initiating new pharmacologic therapy.Reference #1: Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. American Journal of Medicine 1986; 81:46-50.Reference #2: Nesher L and Rolston KV. Neutropenic Enterocolitis, a Growing Concern in the Era of Widespread Use of Aggressive Chemotherapy. Clinical Infectious Disease 2013; 56: 711-717.Reference #3: Shamberger RC, Weinstein HJ, Delorey MJ, Levey RH. The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 1986; 57:603-609DISCLOSURE: The following authors have nothing to disclose: Douglas Eddy, Joseph Guileyardo, Adan MoraNo Product/Research Disclosure Information.
-
BronchiectasisSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Evaluation of morbidity and risk factors for mortality in hospitalized patients with acute exacerbation of bronchiectasis. ⋯ The following authors have nothing to disclose: Maria João Oliveira, Daniel Vaz, Daniel Coutinho, Margarida Dias, Maria do Céu BritoNo Product/Research Disclosure Information.
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To compare the long-term effect of riociguat in PAH patients in FC I/II versus FC III/IV at PATENT-1 baseline. ⋯ Gisela Meyer: Consultant fee, speaker bureau, advisory committee, etc.: Gisela Meyer has received advisory board and speaker fees from Bayer, Lilly and GlaxoSmithKline. Nazzareno Galiè: Grant monies (from industry related sources): Nazzareno Galiè received grant money paid to his institution by Bayer., Consultant fee, speaker bureau, advisory committee, etc.: Nazzareno Galiè received consulting fees, honorariums and/or support for travel to meetings from Bayer. Friedrich Grimminger: Grant monies (from industry related sources): Friedrich Grimminger has received grant money paid to his institution by Bayer HealthCare., Consultant fee, speaker bureau, advisory committee, etc.: Friedrich Grimminger has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare. Ekkehard Grünig: Consultant fee, speaker bureau, advisory committee, etc.: Ekkehard Grünig received support for travel to meetings from Bayer Pharma. Marc Humbert: Consultant fee, speaker bureau, advisory committee, etc.: Marc Humbert has received consultancy fees and payment for lectures including service on speakers bureaus from Bayer. Zhi-Cheng Jing: Consultant fee, speaker bureau, advisory committee, etc.: Zhi-Cheng Jing has received consultancy fees and payment for lectures including service on speakers bureaus from Bayer. Anne M. Keogh: Grant monies (from industry related sources): Anne M. Keogh has received grant money paid to her institution from Bayer., Consultant fee, speaker bureau, advisory committee, etc.: Anne M. Keogh has received consultancy fees from Bayer. David Langleben: Grant monies (from industry related sources): David Langleben received grant money paid to his institution from Bayer Inc., Consultant fee, speaker bureau, advisory committee, etc.: David Langleben received consulting fees/honorarium, paid to his institution by Bayer Inc., Other: David Langleben received fees for participation in review activities, paid to his institution by Bayer Inc. Lewis J Rubin: Consultant fee, speaker bureau, advisory committee, etc.: Lewis J. Rubin has received consulting fees, honorarium and/or support for travel to meetings from Bayer, Pfizer, Actelion, GlaxoSmithKline, United Therapeutics, Gilead, GeNo, Aires, Regeneron and Liquidia., Other: Lewis J. Rubin has received fees for participation in review activities from Bayer, Pfizer, Actelion, GlaxoSmithKline, United Therapeutics, Gilead, GeNo, Aires, Regeneron and Liquidia. Arno Fritsch: Shareholder: Arno Fritsch has received stock/stock options from Bayer HealthCare., Employee: Arno Fritsch is a full-time employee of Bayer HealthCare. Neil Davie: Employee: Neil Davie is a full-time employee of Bayer HealthCare. Hossein-Ardeschir Ghofrani: Grant monies (from industry related sources): Hossein-Ardeschir Ghofrani has received grant money paid to his institution by Bayer HealthCare., Consultant fee, speaker bureau, advisory committee, etc.: Hossein-Ardeschir Ghofrani has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare.Riociguat is an investigational new drug currently in process for registration submission to health authorities, after successful finalisation of a RCT in patients with PAH.
-
OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Home single-channel nasal pressure (HNP) may be an alternative to polysomnography (PSG) for obstructive sleep apnea (OSA) diagnosis but no cost studies have been carried out. Automatic scoring is simpler but generally less effective than manual scoring. Objectives: To determine the diagnostic efficacy and cost of both scorings (automatic and manual) compared with PSG, taking as a polysomnographic OSA diagnosis a clinical-epidemiological apnea-hypopnea index (AHI) cut-off point (≥5) and a clinical-therapeutic AHI cut-off point (≥15). ⋯ The following authors have nothing to disclose: Juan F. Masa, Joaquín Durán-Cantolla, Francisco Capote, Marta Cabello, Jorge Abad, Francisco Garcia-Rio, Antoni Ferrer, Merche Mayos, Nicolás Mangado, Mónica de la Peña, Felipe Aizpuru, Ferran Barbé, Jose M. MontserratNo Product/Research Disclosure Information.
-
Infectious Disease Case Reports Posters IIISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Hemoptysis in the presence of TB, often massive. It is even fatal once its accompanied with Rasmussen's aneurysm with concomitant parasitic infection such as paragonimiasis .These diseases as co-infection are rarely encountered. ⋯ Conventional CT and multidetector CT angiography are quick and noninvasive ways to locate the site of bleeding, determine the cause of bleeding and sputum microroscopy should be mandatory in patients living in the tropical areas.Reference #1: Cleveland Clinic Journal of Medicine August 2008 vol. 75 8 601-607DISCLOSURE: The following authors have nothing to disclose: Gener Idor, Charisma Idor, Cherry ann SerraNo Product/Research Disclosure Information.